ACTRN12621001739808尚未招募2 期
Assessing the safety and efficacy of semaglutide for the treatment of obesity and metabolic risk factors post-liver transplant
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 70 Years（—）
- 性别
- All
入选标准
- •Patients who have undergone liver transplant between 6 months and 5 years prior to enrolment with:
- •BMI >27 in conjunction with any additional risk factor for metabolic disease (index liver transplant for NAFLD, diabetes mellitus, hyperlipidemia, personal or first degree family history of coronary artery disease, HTN or past or active smoking status)
排除标准
- •Active cancer
- •Active infection
- •Frailty (hand grip strength <2 standard deviations below the age and gender-specified mean)
- •Age <18 years or >70 years
- •Prior pancreatitis
- •Previous bariatric surgery
- •Use of anti-obesity medication 90 days before enrollment
- •Use of GLP-1 analogue 90 days before enrollment
- •Stage 4 chronic kidney disease (eGFR <30mL/min)
- •Symptomatic New York Heart Association stage III or IV heart failure
- •Child Pugh B or C cirrhosis
- •Unable to provide consent
研究者
相似试验
尚未招募
Unknown
A study on the safety and efficacy of semaglutide in obese patientsObsesity patientsJPRN-UMIN000053714Kitasato University50
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageEUCTR2018-004484-31-DEovo Nordisk A/S69
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageNon-alcoholic steatohepatitis Compensated liver cirrhosisMedDRA version: 20.1 Level: PT Classification code 10053219 Term: Non-alcoholic steatohepatitis System Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.0 Level: LLT Classification code 10024667 Term: Liver cirrhosis System Organ Class: 10019805 - Hepatobiliary disordersEUCTR2018-004484-31-ESovo Nordisk A/S69
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageEUCTR2018-004484-31-GBovo Nordisk A/S69
进行中（未招募）
1 期
A research study on how semaglutide works in people with fatty liver disease and liver damageEUCTR2018-004484-31-FRovo Nordisk A/S71